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ABSTRACT 
Objective: In the Spinal muscular atrophy [SMA] genes [SMN1 and SMN2 genes]; the CRE-II elements at -400 bp in the promoter region of the SMN 
genes and CRE-I element at +108 bp in the exon 1 of the SMN genes, are reported to have a role in c-AMP induce expression of the SMN genes 
through its binding affinity to CREB-1. This study was designed to determine the role of CRE sites in the circumscribing the clinical severity of SMA.  
Methods: Direct sequencing was performed for the PCR products of the promoter regions of the SMA patients with homozygous deletion of SMN1, 
different copy number of SMN2 and NAIP non deletion.  
Results: No variation among the CRE-I and CRE-II sites was found in all the clinical types as compare to normal healthy control showing no role of 
CRE sites in circumscribing the clinical severity of SMA. 
Conclusion: There was no sequence variation found in the CRE binding sites in the three different clinical types of SMA reflecting no role of CRE 
binding sites in circumscribing the clinical severity of SMA.  
Keywords: SMA, CRE-II, CREB, Promoter of SMN gene. 
 
INTRODUCTION 
In some patients of Spinal Muscular Atrophy [SMA] with 
homozygous deletion of the SMN1 gene and 2 copies of SMN2 gene, 
the differences in the severity of SMA suggests that the production of 
the FL-SMN protein may be different in different clinical types even 
with the same number [2 copies] of the SMN2 gene [1]. Increased 
expression of the SMN genes through froskolin or BT2 which act 
through CRE sites in all clinical severities [2] of SMA reflects these 
compounds must have no effect if CRE binding site is mutated. This 
study aimed to analyze the variation in the CRE binding sites of the 
normal healthy individuals and patients of SMA from different 
clinical types. The study could be very significant in defining the 
difference in transcriptional control, variation among promoter of 
healthy compared to promoter of SMA patients and also variations 
among the promoter of SMN2 gene among SMA patients from 
different clinical types with CRE-I site at +108 bp and CRE-II element 
in at -400 bp upstream in the reported sequence for the promoter 
region of the SMN2 gene [3].  
MATERIALS AND METHODS 
Patients’ recruitment 
A total of 134 patients were included in this study by applying single 
proportion formula [n > [z α / Δ]2
DNA extraction and SMA genes analysis 
x P [1-P]], where n [96] is the 
minimum sample required, z α was set at 1.96 for allowing Type I 
error for 5% [0.05], Δ [0.1] is the estimation of having mutation in 
SMN2 promoter region and P [0.5] is the proportion of having 
mutation in SMN2 promoter region. The diagnosis was based on the 
clinical criteria as setup by the 59th and 93rd ENMC International 
Workshop on SMA in 1998 and 2001 respectively [4, 5]. The 
clinically summary of all the patients was reviewed at Hospital 
Universiti Sains Malaysia [HUSM] by the pediatric neurologist and 
58 patients were excluded from the study as the criteria of SMA 
international consortium were not fulfilled by them. This study was 
conducted with the permission of USM ethical clearance and was 
funded by the grant from ministry [SAGA grant].  
The samples of remaining 69 patients were received from different 
hospitals all over Malaysia. Informed consent was obtained prior to 
blood taking. Total of 69 normal healthy individuals were used as a 
negative control. DNA was extracted from whole blood using a DNA 
extraction kit, GeneAll® ExgeneTM Blood SV [GeneAll Biotechnology 
Co. Ltd., Korea]. The DNA was quantified using Eppendrof DNA 
spectrophotometer. The 42 patients with homozygous SMN1 
deletion were analyzed for the copy number analysis of the SMN2 
gene and NAIP deletion [6,7]. This part of the analysis has been 
reported previously by our group [8]. 
Molecular analysis of the CRE sites 
A total of 10 patients were selected for further analysis. All these 
patients were checked for the presence of the NAIP gene to remove 
any clinical bias in the methodology and disease severity. Firstly, we 
included only the patients with 2 copies of the SMN2 gene. Later, 
nucleotide variation analysis was also performed on patients with 3 
and 4 copies of the SMN2 gene in different clinical types considering 
the previous report stating that the patients with more than 2 copies 
of SMN2 and different clinical severity shows same levels of FL-SMN 
[1]. As previously reported [2], the CRE-II element was analyzed for 
the molecular variation in normal healthy individuals and SMA 
patients from different clinical types. The primers were designed 
manually using the SMN2 promoter sequence Gen Bank entry 
[GenBank accession number; AF187725]. Two primers were 
designed, forward P3932 [5’TGAGCTCAGGAGTTCGAGAC3’] and 
complementary reverse PCR [5’GGCGTGTATATTTTTCATTTCTC3’] 
for analyzing CRE-I site and for CRE-II we made use of primers for 
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exon 1 with slight modification in annealing temperature [9]. For 
CRE-I, The PCR was performed for a total of 30 cycles with the Ta of 
58o
The DNA sequencing for the CRE-II binding site was performed for 
the 10 patients and 3 normal healthy individuals [as a negative 
control] using direct sequencing of the PCR product; amplified with 
universal M13 reverse and M13 forward [-20] universal primers in 
the backbone of pTOPO2.1e. The plasmids with inserts were 
confirmed by digestion using DraI site in the insert and pTOPO 2.1 e 
back bone. For the CRE-I site, no cloning was performed prior to 
sequencing and PCR amplified product of exon 1 was subjected 
directly to sequencing using specific primers [9]. The PCR products 
were subjected to direct sequencing after purification using 
Promega kit. The PCR products were sequenced with the Big Dye 
Terminator Cycle Sequencing Ready Reaction kit with Amplitaq DNA 
polymerase. FS [Perkin-Elmer, applied Biosyntech Division], on an 
automated ABI PRISM 3100 DNA sequencer [Perkin-Elmer, Applied 
Biosystem Division], following the manufacturer’s instructions. In 
case of doubtful sequence [GT-rich or G-rich region, secondary 
structure, certain sequence context or motifs], sequencing reactions 
were performed with the dGTP Big Dye Terminator Ready Reaction 
kit [Perkin-Elmer, Applied Biosystem Division]. Sequences were 
aligned using the ClustalX program and Vector NTI Suite 9. In case of 
ClustalX, the alignment results were being stored as MSF files using 
Gene Doc software. 
C and an internal control of 200 bp. The PCR products were 
visualized on agarose gel electrophoresis with a concentration of 
1.2% of agarose and 10mg/ml ethidium bromide. The image was 
captured using an Alpha Innotech image analyzer. The 720 bp 
amplified PCR products from normal healthy individual [n=2] and 
SMA patients were then cloned into pCR®2.1-TOPO® cloning vector 
[A] from Invitrogen. The supplied instructions were followed and 
the ligation mixture was prepared to transform into freshly 
prepared TOP10 E. coli competent cells. The average transformant 
efficiency of 8.2 - 8.5e-2 [transformants /μg DNA] was achieved 
against ampicillin [100μg/ml] and selected by blue white screening 
with IPTG concentration of 20% w/v. The transformants were 
confirmed further by PCR and the plasmid extraction was done 
using commercial plasmid extraction kit was used [Qiagen Inc. 
28153 Avenue Stanford, Valencia, CA 91355, USA]. However, the 
protocol was based on an alkaline lysis method of plasmid 
extraction. The DNA concentration of the plasmid DNA was 
quantified using Eppendrof DNA spectrophotometer.  
DNA sequencing and data analysis 
RESULTS AND DISCUSSION 
All three forms of SMA are caused by loss or mutation of the 
telomeric survival motor neuron gene [SMN1], but the centromeric 
survival motor neuron gene [SMN2] is retained [10]. As we know 
now, that, molecules capable of inducing SMN2 expression [11, 12] 
or altering the splicing of SMN2 such that more full-length SMN 
transcript is produced have been identified [11, 13]. At the present 
time, there is limited information on the mode of action of these 
compounds as well as the protein complexes that interact with the 
SMN promoter. The CREB/ATF family of transcriptional activators 
consists of multiple protein species that recognize nearly identical 
binding sites [13]. It has also been reported that there is a novel 
cAMP response element, CRE-I [TGACGACA] in the promoter of the 
SMN gene at position -400 bp along with CRE-II binding site 
[TGACGACT] at +108 bp downstream of the SMN gene [1, 15] that 
can interacts with the cAMP response element binding CREB family 
of protein [1]. Even with the sequence similarity of 87.5%, Sarmila 
and colleagues reported CRE-II element to be involved in c-AMP 
induced over expression of the SMN genes under the effect of CREB-
1 protein [1]. In 2003, Sumner and colleagues reported valproic acid 
to increase the SMN level in SMA patients [16] which was followed 
by the findings of Sarmila et al., 2003, which reported the increased 
over expression of CREB-1 protein and SMN2 in the presence of 
dibutyryl cAMP and froskolin [1].  
  
Table 1: Characterization of the SMA patients used for the molecular analysis of the CRE-I and CRE-II elements, NA = Non applicable 
Patients SMA Gender Race Consanguinity  Tongue fasciculation  Muscle biopsy 
1 Type I Male Malay No Yes Not done 
2 Type I Female Malay No Yes Not done 
3 Type II Female  Malay NA Yes NA 
4 Type II Male  Malay Adapted  No Not done 
5 Type II Female Malay No No Neurogenic muscle atrophy 
6 Type III Female Malay No NA Not consented for second time 
7 Type III Male Malay No Yes Not done 
8 Type III Male Malay No No Selective group atrophy of muscle 
9 Type III Male Malay No No Not done 
10 Type III Female Malay No No Consistent with SMA 




NAIP  SMN2 copy 
 no. 
Onset age EMG 
1 deleted deleted non deleted 1 Since birth Giant motor potential 
2 deleted deleted non deleted 2 3 month Not done 
3 deleted deleted non deleted 2 NA fibrillation potential, giant potential 
4 deleted deleted non deleted 3 15 months Consistent with SMA 
5 deleted deleted non deleted 4 1 year Nerve conduction normal 
6 deleted deleted non deleted 2 18 months spontaneous fibrillation at rest with denervation pattern 
7 deleted deleted non deleted 2 Since 14 years old Giant motor potential 
8 deleted deleted non deleted 3 24 months Giant muscle action potential 
9 deleted deleted non deleted 4 Since 1 year Not done 
10 deleted deleted non deleted 4 8 months Supportive of SMA 
 
The differences in severity among SMA patients have prompted 
researchers to investigate the genomic variations that contribute to 
these phenotypes. Variation in the number of copies of the SMN2 
gene contributes to the severity of SMA [17]. Furthermore, given 
that SMN2 is known to be transcribed, a difference in SMN2 copy 
number would also translate into a variation in the amount of 
functional protein produced. It was demonstrated that there is a 
correlation between disease severity and SMN protein levels and a 
higher ratio of SMN2/SMN1 gene dosage in the parents of SMA type 
II and III patients, compared with the parents of type I patients [17].  
The SMN2 promoter sequence of normal individuals submitted 
by Boda et al., [1999], has been a reference for all researchers 
and we made use of the same sequence for designing of primers 
for CRE-I element. We started our analysis with the total of 3 
patients [one patient from each type], patient number 2, 3 and 6 
[table 1]. 
The CRE-II binding site analysis was performed in these 3 patients 
followed by the variation analysis of the CRE-II binding site in 
promoter region in other 7 patients [type I = 1, type II = 2, type III 
=4]; as mentioned in table 1 [patient number 1, 4, 5, 7, 8, 9, 10]. All 
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these patients are with more than 2 copies of SMN2 gene except 
patient no. 1 which has only 1 copy of the SMN2 gene. All these 
patients are reported to be non deleted for NAIP gene which was 
analyzed to avoid any experimental and severity bias considering 
the SMA modifying genes [8].  
Furthermore, the increased expression of the SMN genes through 
froskolin or BT2 which act through CRE sites in all SMA types 
reflects these compounds must have no effect if CRE site is mutated 
[1]. The absence of any mutation and positive effect of forskolin and 
Bt2 on CRE sites [2] in different clinical types of SMA confirms that 
the CRE site can only be used for c-AMP induced expression of SMN 
genes. However, the CRE sites might not be the cause of induction of 
SMA with no role in circumscribing the clinical severity of SMA. The 
absence of any variation in the CRE elements [fig. 1] in the promoter 
region and exon 1 of the SMN2 gene in SMA patients from different 
clinical types compare to the promoter region of the SMN2 gene in 
normal healthy individuals, suggested a role of other epigenetic 
factors and transcription factors which might be influential in 
controlling and coregulating the induction of SMN expression within 
4.6kb promoter region of the SMN2 gene, hence, may influence the 
SMA severity in patients from different clinical severities with same 
copy number of SMN2 gene. 
 
Fig. 1: The molecular analysis of the CRE-I and CRE-II binding 
sites in the SMA patients from different clinical types. N= 
Normal healthy individual, P[n]= SMA patient 
 
CONCLUSION  
There was no molecular variation found in the CRE-I and CRE-II sites 
in any of the clinical types of the SMA patients as compared to the 
normal healthy individuals in the expected promoter region of the 
SMN2 gene in SMA patients. The results suggested that the CRE-I and 
CRE-II elements have no role in severity of SMA in different clinical 
types.  
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